Feb 17 2011
Integra LifeSciences Holdings Corporation announced today that it has entered into an exclusive worldwide license and development agreement with Stout Medical Group, LP to develop and commercialize an expandable interbody device. The license allows Integra to develop a device that surgeons could implant into the disc space using minimally invasive techniques, enabling surgeons to perform a potentially safer, simpler procedure. During an interbody fusion procedure, this novel technology is designed to allow a surgeon to adjust the height in-situ according to the patient's needs.
"The expandable interbody fusion platform is an important and innovative addition to our minimally invasive device portfolio," said Brian Larkin, Integra's President, Global Spine/Orthobiologics, and Head of Strategic Development. "This agreement leverages our considerable expertise in business development, and underscores our commitment to provide new technology to our spine distribution partners."
The products derived from this technology will participate in the greater than $750 million lumbar interbody fusion device market.
"Stout Medical Group strongly believes in working with its licensing partners in the development and commercialization of its technologies. We're very excited to be working with Integra on the expandable interbody platform," said Tom Molz, President and CEO of Stout Medical Group.
Source: Integra LifeSciences
Revolutionizing diabetes management with reliable blood glucose monitoring without finger pricking